Does GLP-1 medication cause the 'Ozempic face' look?

What did @alldaybreezy actually say?

The creator looked at photos of Olivia Wilde and argued that dramatic facial changes are a scary consequence of GLP-1 drugs. They claimed these medications are "not FDA approved" and "not approved by any doctor physician," and warned that appearance-related side effects "could be irreversible." They also name-dropped "reddit two tries," which appears to be a mangled reference to retatrutide.

To be fair, there's a real concern buried in here. Rapid weight loss can cause noticeable facial changes, sometimes called "Ozempic face" in popular media. That part is grounded in something real. But the video wraps a legitimate observation in a pile of factual errors, and those errors matter when people are making health decisions based on a 60-second clip.

Does the science back this up?

Not really, at least not for the key claims. Semaglutide (Wegovy) received FDA approval for chronic weight management in adults in June 2021. Tirzepatide (Zepbound) was approved for the same indication in November 2023. These are not fringe compounds. They have gone through Phase 3 clinical trials involving tens of thousands of participants.

On the facial changes question, there is real clinical discussion happening. Rapid fat loss redistributes volume in the face, and some patients and clinicians have noted a hollowed or aged appearance. A 2023 commentary in JAMA Dermatology (Hartman et al.) discussed this phenomenon. But "irreversible" is too strong a word. Dermatologists routinely address volume loss with fillers or lifestyle adjustments, and slower weight loss timelines appear to reduce the effect. Calling these changes permanent as a rule is not supported by current evidence.

What did they get wrong (or right)?

Wrong: "These things are not FDA regulated." Semaglutide and tirzepatide are FDA-approved prescription drugs, regulated under the same framework as any other medication. This claim is simply false.

Wrong: "Not approved by any doctor physician." These drugs are prescribed by licensed physicians every day. The STEP trials for semaglutide (Wilding et al., 2021, NEJM) involved clinicians across multiple countries. They are actively recommended in obesity medicine guidelines.

Partially right: Facial changes from rapid weight loss are real and documented. The creator is not inventing this. The concern about dramatic body composition changes happening faster than a person's skin and facial tissue can adapt is a legitimate clinical conversation.

Wrong: Retatrutide (what they seemed to be calling "reddit two tries") is actually not FDA-approved yet. It remains in clinical trials as of early 2025. Lumping it in with approved drugs as if they are all equally unregulated misrepresents the entire category.

What should you actually know?

GLP-1 receptor agonists are among the most studied drug classes in recent obesity medicine history. Semaglutide's approval was based on the STEP program, which showed roughly 15 percent average body weight reduction over 68 weeks (Wilding et al., 2021, NEJM). Tirzepatide showed even larger effects in the SURMOUNT trials (Jastreboff et al., 2022, NEJM).

That does not mean side effects do not exist. They do. Nausea, gastrointestinal issues, and yes, changes in facial appearance from rapid fat loss are all documented. The right response to that is a conversation with a licensed clinician who can weigh your individual risk profile, not a TikTok video warning you that an FDA-approved drug is unregulated.

• Always verify whether a medication is FDA-approved before making decisions based on social media claims.
• Facial volume changes from weight loss are real but are generally manageable and not automatically permanent.
• Retatrutide is a separate compound still in trials. It should not be grouped with approved medications without that distinction being clear.